Dems Aim To Change FDA Approach To Cannabis As Rescheduling Proceeds

As the Biden administration takes steps to move marijuana to a less-restrictive drug “schedule” allowing for more use in medical contexts, prominent Senate Democrats have reintroduced a bill that would create a new regulatory pathway at FDA and a Center of Cannabis Products. Even if marijuana is rescheduled, FDA must still approve products containing cannabis, and the legislation would make it easier for the agency to navigate such approvals and would completely nix cannabis as a controlled substance. The federal...